Navigation Links
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
Date:8/4/2009

of additional tests to personalize the treatment of cancer; the company's expectations regarding the commercialization of a test for colon cancer and the proposed timing of commercialization; the company's expectation that improved pricing yields will favorably impact product revenue; the company's expectations regarding full year 2009 total revenue, net loss and test results delivered; the outcome, success or results of clinical trials; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners. <
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 The consumption of compound fertilizers ... recession and high prices in 2008. However, the situation ... keeps on gaining momentum now. , To date, the ... than 100,000 thousand tonnes. No considerable growth was registered ... capacity rocketed during 2012-2013, registering 11% growth as against ...
(Date:3/27/2015)... 27. März 2015  Peter Walter wurde ... Science für seine bahnbrechende Arbeit ausgewählt, die ... transportiert werden, sowie für die Entschlüsselung der ... auf Stress nutzen, der mit der Ansammlung ... Professor für Biochemie an der University of ...
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Neogen CEO adopts 10b5-1 Trading Plan 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2
... Aug. 20 Advanced Cell,Technology, Inc. (OTC Bulletin ... conditions, it plans to privately offer up to ... timing of the,closing of the offering will be ... are expected to be used to fund working ...
... CEO Mark McDade to resign for personal reasons ... BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced ... executive officer (CEO), Mark McDade,found no credible evidence ... by McDade to corroborate the various allegations,investigated. The ...
... Supplier Presents Today at Small Cap Financial ... ... ), a leading provider of nitinol and polymer components to the,medical device ... for the fourth fiscal,quarter ended June 30, 2007, an increase of over ...
Cached Biology Technology:Advanced Cell Technology Announces Proposed Financing 2Advanced Cell Technology Announces Proposed Financing 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 2Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 3Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 4
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Iris Biometrics - Global Strategic Business Report" ... worldwide markets for Iris Biometrics in US$ Thousands. The report ... , Japan , Europe ... East , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... study, published in the March issue of Human Nature ... difference in their subjective ratings of photos of men when ... who did not have sexual partners spent more time evaluating ... No such difference was found between men who had sexual ...
... , This release is available in <A ... spread and devastating natural disaster across the globe. It ... annual damage of about 1.5 billion. The figure is ... few years (Association of British Insurers). Floods that took ...
... of environmental change? Evolvequickly. A new article in The ... new habitats developed new and advantageous traits in just a ... to look at adaptation and survival in a wild population. ... the University of California, Riverside studied 200 guppies that had ...
Cached Biology News:Single women gaze longer 2Next-generation software system for flood warning and risk analysis to be developed 2When evolution is not so slow and gradual 2
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White lyophilized ... GAS. A cell-permeable, reversible inhibitor of γ-secretase. ... (ED 50 = 2.6 μM) ... = 2.7 μM) in HEK293 cells stably ...
...
Biology Products: